Schizophrenia and Bipolar I Disorder: Understanding Patient Needs to Guide Targeted Treatment Approaches
April 26, 2023
April 26, 2024
Psychology, Psychiatry, Primary care, Nurse practitioners, Physician assistants, mental health specialists
This activity is jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC .
In collaboration with the Schizophrenia & Psychosis Action Alliance (S&PAA)
This activity is supported by educational grants from Alkermes, Inc. and Indivior Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
The target audience for the activity are psychologists, psychiatrists, primary care physicians, nurse practitioners, physician assistants in psychiatry and primary care, and other mental health specialists.
People living with schizophrenia or bipolar I disorder face several challenges in managing their conditions, including side effects that impact QoL, diversity-related barriers to care, and feelings of isolation. When devising or altering treatment plans, clinicians must be mindful of these challenges, as well as other patient- and treatment-related factors that can affect treatment success.
Join a panel of expert psychiatrists to discuss the unique challenges facing patients with schizophrenia or bipolar I disorder, including real-world patient experiences shared in pre-recorded interviews. Panelists will review limitations of existing therapies, and new and emerging treatment options. Clinicians will be prepared to devise patient-focused treatment plans that integrate patient needs and goals.
At the conclusion of this activity, participants will be able to:
- Discuss persistent real-world challenges faced by patients living with schizophrenia or bipolar I disorder
- Consider patient- and treatment-related factors when formulating treatment plans for patients living with schizophrenia or bipolar I disorder
- Evaluate clinical evidence for newly approved and emerging agents in schizophrenia and bipolar I disorder management
René S. Khan, MD, PhD
Esther and Joseph Klingenstein Professor & Chair
Department of Psychiatry and Behavioral Health System
Icahn School of Medicine at Mount Sinai
Christoph U. Correll, MD
Professor of Psychiatry
Zucker School of Medicine at Hofstra/Northwell
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine, Berlin, Germany
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Enduring Credit Designation Statement
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
- René S. Khan, MD, PhD
- Consultant/Advisory Board: Alkermes, Merck, Sunuvion
- Christoph U. Correll, MD
- Grant/Research Support: Janssen, Takeda
- Honoraria for non-CME: AbbVie, Angelini, Aristo, Damitsa, Gedeon Richter, Hikma, IntraCellular Therapies, Janssen/J&J, Lundbeck, Mitsubishi Tanabe Pharma, Mylan, Otsuka, Recordati, Seqirus, Sunovion, Takeda, Viatris
- Consultant/Advisory Board: AbbVie, Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Gedeon Richter, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, Mindpax, Mylan, Neurocrine, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris
- Non-Mutual funds Stock Ownership/Stock options: Stock option holder only of Cardio Diagnostics, Mindpax, LB Pharma and Quantic
- Royalties paid to you: UpToDate
The PIM planners and managers have nothing to disclose. The PlatformQ Health Education, LLC planners and others have nothing to disclose.
Disclosure of Unapproved/Off Label Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees to participate in this activity. To participate in the activity, go to www.PsychiatryCareLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Please contact the Postgraduate Institute for Medicine at firstname.lastname@example.org.
For any technical issues or issues with your CME Certificate, please contact PsyciatryCareLive at 877-394-1306 or at Support@PsyciatryCareLive.com.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting support@PlatformQHealth.com with the subject line “Data Request”